In this way, we would decipher the two chance discoveries by Doug Wolf: the antitumor action of low-dose estrogen following LTED in MCF-7 cells and a mutation Asp351Tyr in the ER of tamoxifen-stimulated breast cancer resistant to tamoxifen. Here, ESR1 is linked to breast cancer.